Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

takeda gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - tablets gastro-resistant - 40mg

Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

takeda gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - tablets gastro-resistant film-coated - 40mg

Unió Europea - anglès - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vaccines - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age.the use of qdenga should be in accordance with official recommendations.

Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

takeda gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - powder for solution for injection - 40mg

Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

takeda gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - powder for solution for injection - 40mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 3.29 mg (equivalent: ixazomib, qty 2.3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 4.3 mg (equivalent: ixazomib, qty 3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 5.7 mg (equivalent: ixazomib, qty 4 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Israel - anglès - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 30 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Israel - anglès - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 90 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)